Inspira Technologies Oxy B.H.N. Ltd. (IINN): Price and Financial Metrics
IINN Price/Volume Stats
| Current price | $1.50 | 52-week high | $1.99 |
| Prev. close | $1.43 | 52-week low | $0.98 |
| Day low | $1.39 | Volume | 25,466 |
| Day high | $1.50 | Avg. volume | 47,452 |
| 50-day MA | $1.40 | Dividend yield | N/A |
| 200-day MA | $1.41 | Market Cap | 11.67M |
IINN Stock Price Chart Interactive Chart >
Inspira Technologies Oxy B.H.N. Ltd. (IINN) Company Bio
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Latest IINN News From Around the Web
Below are the latest news stories about INSPIRA TECHNOLOGIES OXY BHN LTD that investors may wish to consider to help them evaluate IINN as an investment opportunity.
Inspira™ Announces 510(k) FDA Submission of INSPIRA™ ART100 Towards CommercializationInspira™ Technologies OXY BHN Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a company aiming to bring a paradigm shift to acute respiratory care by empowering breathing without lungs, announced it had submitted its INSPIRA ART 100, a cardio-pulmonary bypass device, to the U.S. Food and Drug Administration (FDA) via the 510(k) pathway, with potential clearance expected during the first half of 2024. |
Inspira (IINN) Advances Foothold in Europe With Extended DealThe extended service agreement complements a previously announced strategic agreement between Inspira (IINN) and Innovimed. |
Inspira™ Signs Agreement Expansion with Innovimed for Clinical Trials of INSPIRA™ ART Respiratory Medical DevicesInspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a company dedicated to advancing acute respiratory care by enabling breathing without lungs, announced today that it has signed a further Service Agreement to supplement its previously announced Strategic Agreement with Innovimed Sp. z o.o ("Innovimed") for planned clinical trials (clinical pilot studies) of the INSPIRA™ ART medical devices. |
Inspira™ Technologies Reports Second Quarter 2023 Financial ResultsInspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a company aiming to revolutionize acute respiratory care, announced today its financial results for the second quarter ended June 30, 2023. |
INSPIRA™ ART100 Completes Usability Study in Boston Massachusetts, U.S.Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce it has completed a Usability Study in Boston, Massachusetts for its INSPIRA ART100 device. |
IINN Price Returns
| 1-mo | 1.35% |
| 3-mo | 0.00% |
| 6-mo | 11.11% |
| 1-year | 8.70% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 16.28% |
| 2022 | -68.99% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...